Subtype
Urothelial Carcinoma
CI-CAN-00004188Explore in graph →
236 active trials5 approved drugs8 evidence items
- NCIt
- C4030
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004188Explore in graph →
Clinical trials
623 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (99)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07705074 | FAPI PET Imaging - An Exploratory Study(FAPIPET) | not yet recruiting | Phase 1 / Phase 2 | 770 | Martin HuellnerOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT03374267 | Registry Platform Urologic Cancer(CARAT) | recruiting | — | 2,230 | iOMEDICO AGINDUSTRY | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06695845 | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | recruiting | Phase 2 | 200 | Jazz PharmaceuticalsINDUSTRY | 3 | Jul 10, 2026 | clinicaltrials |
| NCT07630155 | Office-Based Ureteroscopy Utilizing a Single Use Digital, Flexible Ureteroscope for Upper Tract Urothelial Carcinoma | recruiting | N/A | 10 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05521698 | A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer | recruiting | Phase 1 | 80 | University of Wisconsin, MadisonOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07302230 | Home-Based Physical Activity Program With Digital App Versus Health Education Group for Improving Physical Activity Among Patients With Non-muscle Invasive Bladder Cancer, The EMPOWER Trial(EMPOWER) | recruiting | N/A | 100 | University of WashingtonOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07118176 | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers | active not recruiting | Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07169734 | A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors | recruiting | Phase 1 / Phase 2 | 180 | Alentis Therapeutics AGINDUSTRY | 8 | Jul 2, 2026 | clinicaltrials |
| NCT07614594 | Non-invasive Urinary Genomics-Based Risk Assessment for Early Urothelial Carcinoma Diagnosis | recruiting | — | 800 | Henan Provincial People's HospitalOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06111235 | A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT | active not recruiting | Phase 3 | 367 | CG Oncology, Inc.INDUSTRY | 2 | Jul 1, 2026 | clinicaltrials |
| NCT06101290 | Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)(LAYOVER) | recruiting | N/A | 150 | University of California, DavisOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07673016 | Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer(INSITE) | recruiting | — | 2,500 | Convergent Genomics, Inc.NETWORK | 2 | Jun 29, 2026 | clinicaltrials |
| NCT07663747 | Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC(FIDELIO) | not yet recruiting | Phase 2 | 56 | The Netherlands Cancer InstituteOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07662863 | Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01)(SPARE-UC-01) | not yet recruiting | Phase 2 | 75 | Fudan UniversityOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03967977 | Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma | active not recruiting | Phase 3 | 420 | BeiGeneINDUSTRY | 2 | Jun 22, 2026 | clinicaltrials |
| NCT07484022 | Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer | recruiting | Phase 1 | 37 | Generate BiomedicinesINDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06967961 | Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers(DP-PAN-CANCER) | recruiting | N/A | 450 | Institut Claudius RegaudOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05092958 | Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study | active not recruiting | Phase 3 | 654 | National Cancer Institute (NCI)NIH | 2 | Jun 12, 2026 | clinicaltrials |
| NCT06630416 | Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors | recruiting | Phase 2 | 64 | Northwestern UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07029256 | Ultrasound-Guided Core Needle Biopsy to Stage Urothelial Carcinoma of the Bladder (US UCB) | recruiting | — | 100 | Mayo ClinicOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07048457 | Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma(CONSOLIdATE-1) | recruiting | Phase 2 | 32 | Yale UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT02717156 | Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors | active not recruiting | Phase 2 | 70 | University of Southern CaliforniaOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07636772 | A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma | not yet recruiting | Phase 2 | 132 | AkesoINDUSTRY | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07629700 | Study of Peripheral Neuropathy in Patients With Advanced Urothelial Cancer Treated With Enfortumab Vedotin and Pembrolizumab With Supportive Neuridase (ENDEAVOR)(ENDEAVOR) | not yet recruiting | N/A | 40 | University of FlorenceOTHER | 0 | Jun 8, 2026 | clinicaltrials |
| NCT07631871 | An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy | not yet recruiting | Phase 2 | 10 | Haihua YuanOTHER | 0 | Jun 8, 2026 | clinicaltrials |
| NCT07631884 | Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor | not yet recruiting | Phase 2 | 15 | Haihua YuanOTHER | 0 | Jun 8, 2026 | clinicaltrials |
| NCT07439120 | Safety and Tolerability Study of 68Ga/177Lu-BRP-020063 in Advanced Solid Tumors | recruiting | Early Phase 1 | 10 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07390617 | A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma | recruiting | — | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT04514484 | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | active not recruiting | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT03291028 | Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma | active not recruiting | — | 15 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04216290 | A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial | active not recruiting | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | May 22, 2026 | clinicaltrials |
| NCT07602010 | Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging | recruiting | — | 150 | Oslo University HospitalOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04388852 | DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers | active not recruiting | Phase 1 | 65 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT06204614 | Drug Screening Using IMD in Bladder Cancer | enrolling by invitation | Early Phase 1 | 18 | Brigham and Women's HospitalOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07591805 | HERO-UTUC: Intravesical RC48 After RNU for HER2+ UTUC(HERO-UTUC) | not yet recruiting | Phase 2 | 49 | RenJi HospitalOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT04969835 | A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours | recruiting | Phase 1 | 158 | Avacta Life Sciences LtdINDUSTRY | 2 | May 15, 2026 | clinicaltrials |
| NCT07557225 | 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors | recruiting | N/A | 200 | Peking University First HospitalOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT03601455 | Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer | active not recruiting | Phase 2 | 13 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05243550 | A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer(ENVISION) | active not recruiting | Phase 3 | 240 | UroGen Pharma Ltd.INDUSTRY | 10 | May 11, 2026 | clinicaltrials |
| NCT05661955 | A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors. | active not recruiting | Phase 1 / Phase 2 | 113 | BeiGeneINDUSTRY | 1 | May 11, 2026 | clinicaltrials |
| NCT06318871 | Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma | active not recruiting | Early Phase 1 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT07087860 | Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers(RECIPE-B1) | recruiting | Phase 2 | 70 | Mayo ClinicOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT05154994 | Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma(RESOLVE) | active not recruiting | Phase 1 | 9 | University of UtahOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT07231809 | Hyperthermic Intravesical Chemotherapy (HIVEC) in BCG-Non-Responsive High-Grade NMIBC Patients(HIVEC) | not yet recruiting | N/A | 50 | AC.TA. S.r.l.INDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT06335667 | mpMRI Compared to Diagnostic TURBT in Patients With Suspected Muscle-Invasive Bladder Cancer | recruiting | N/A | 30 | University of California, IrvineOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05646485 | Bladder Cancer Screening Trial | recruiting | N/A | 1,000 | University of Texas Southwestern Medical CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT05946993 | Linking In With Advice and Supports for Men Impacted by Metastatic Cancer(LIAM Mc) | active not recruiting | N/A | 72 | University College CorkOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT06682728 | Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence | recruiting | Phase 2 | 23 | University of California, IrvineOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07241793 | Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)(TRAIN-UC-01) | recruiting | Phase 2 | 96 | Sun Yat-sen UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jul 15, 2026source: clinicaltrials